HEADER TRANSFERASE 16-MAY-11 2YIS TITLE TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE. COMPND MOL_ID: 1; COMPND 2 MOLECULE: MITOGEN-ACTIVATED PROTEIN KINASE 14; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: MAP KINASE 14, MAPK 14, CYTOKINE SUPPRESSIVE ANTI- COMPND 5 INFLAMMATORY DRUG-BINDING PROTEIN, CSAID-BINDING PROTEIN, CSBP, MAP COMPND 6 KINASE MXI2, MAX-INTERACTING PROTEIN 2, P38 KINASE, MITOGEN-ACTIVATED COMPND 7 PROTEIN KINASE P38 ALPHA, MAP KINASE P38 ALPHA, SAPK2A; COMPND 8 EC: 2.7.11.24; COMPND 9 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS TRANSFERASE, INHIBITOR SBDD KINASE, CELL CYCLE EXPDTA X-RAY DIFFRACTION AUTHOR D.S.MILLAN,M.ANDERSON,R.BAZIN,M.E.BUNNAGE,J.L.BURROWS,K.J.BUTCHER, AUTHOR 2 P.G.DODD,T.J.EVANS,D.A.FAIRMAN,S.J.HUGHES,S.L.IRVING,I.C.KILTY, AUTHOR 3 A.LEMAITRE,R.A.LEWTHWAITE,A.MAHNKE,J.P.MATHAIS,J.PHILIP,C.PHILLIPS, AUTHOR 4 R.T.SMITH,M.H.STEFANIACK,M.YEADON REVDAT 2 08-MAY-24 2YIS 1 REMARK REVDAT 1 30-NOV-11 2YIS 0 JRNL AUTH D.S.MILLAN,M.E.BUNNAGE,J.L.BURROWS,K.J.BUTCHER,P.G.DODD, JRNL AUTH 2 T.J.EVANS,D.A.FAIRMAN,S.J.HUGHES,I.C.KILTY,A.LEMAITRE, JRNL AUTH 3 R.A.LEWTHWAITE,A.MAHNKE,J.P.MATHIAS,J.PHILIP,R.T.SMITH, JRNL AUTH 4 M.H.STEFANIAK,M.YEADON,C.PHILLIPS JRNL TITL DESIGN AND SYNTHESIS OF INHALED P38 INHIBITORS FOR THE JRNL TITL 2 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. JRNL REF J.MED.CHEM. V. 54 7797 2011 JRNL REFN ISSN 0022-2623 JRNL PMID 21888439 JRNL DOI 10.1021/JM200677B REMARK 2 REMARK 2 RESOLUTION. 2.00 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER 2.9.6 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.00 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 23.43 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 98.3 REMARK 3 NUMBER OF REFLECTIONS : 25518 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.216 REMARK 3 R VALUE (WORKING SET) : 0.214 REMARK 3 FREE R VALUE : 0.255 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.060 REMARK 3 FREE R VALUE TEST SET COUNT : 1290 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 13 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 2.00 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 2.08 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 98.26 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 2556 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.2416 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2414 REMARK 3 BIN R VALUE (WORKING SET) : 0.2392 REMARK 3 BIN FREE R VALUE : 0.2829 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.56 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 142 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2635 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 67 REMARK 3 SOLVENT ATOMS : 247 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 33.45 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 35.28 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 4.07140 REMARK 3 B22 (A**2) : 7.90700 REMARK 3 B33 (A**2) : -11.97840 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.268 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.212 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.178 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.199 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.174 REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.927 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.908 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 2770 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 3765 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 934 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : 89 ; 2.000 ; HARMONIC REMARK 3 GENERAL PLANES : 397 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 2770 ; 20.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 350 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 3336 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 BOND ANGLES (DEGREES) : 1.11 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 3.05 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 19.11 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2YIS COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 16-MAY-11. REMARK 100 THE DEPOSITION ID IS D_1290048303. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : NULL REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : NULL REMARK 200 DETECTOR MANUFACTURER : NULL REMARK 200 INTENSITY-INTEGRATION SOFTWARE : NULL REMARK 200 DATA SCALING SOFTWARE : NULL REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 25518 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.000 REMARK 200 RESOLUTION RANGE LOW (A) : 23.500 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 1.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.0 REMARK 200 DATA REDUNDANCY : 3.700 REMARK 200 R MERGE (I) : 0.06000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 15.0000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : NULL REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: OTHER REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: NONE REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 45.80 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.27 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 32.72500 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 38.57000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 37.05000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 38.57000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 32.72500 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 37.05000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 SER A 2 REMARK 465 GLN A 3 REMARK 465 GLU A 4 REMARK 465 GLY A 33 REMARK 465 ALA A 34 REMARK 465 TYR A 35 REMARK 465 ASN A 115 REMARK 465 ILE A 116 REMARK 465 VAL A 117 REMARK 465 LYS A 118 REMARK 465 CYS A 119 REMARK 465 GLN A 120 REMARK 465 LYS A 121 REMARK 465 LEU A 122 REMARK 465 GLY A 170 REMARK 465 LEU A 171 REMARK 465 ALA A 172 REMARK 465 ARG A 173 REMARK 465 HIS A 174 REMARK 465 THR A 175 REMARK 465 ASP A 176 REMARK 465 ASP A 177 REMARK 465 GLU A 178 REMARK 465 MET A 179 REMARK 465 THR A 180 REMARK 465 GLY A 181 REMARK 465 ASP A 354 REMARK 465 GLN A 355 REMARK 465 GLU A 356 REMARK 465 GLU A 357 REMARK 465 MET A 358 REMARK 465 GLU A 359 REMARK 465 SER A 360 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LEU A 353 CA C O CB CG CD1 CD2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LYS A 15 -8.31 69.72 REMARK 500 PHE A 99 103.79 -51.38 REMARK 500 ARG A 149 -12.76 74.88 REMARK 500 ASP A 150 39.68 -140.62 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A2017 DISTANCE = 6.13 ANGSTROMS REMARK 525 HOH A2022 DISTANCE = 6.11 ANGSTROMS REMARK 525 HOH A2027 DISTANCE = 6.24 ANGSTROMS REMARK 525 HOH A2073 DISTANCE = 6.80 ANGSTROMS REMARK 525 HOH A2102 DISTANCE = 6.30 ANGSTROMS REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE YIS A 1353 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE I46 A 1354 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2BAJ RELATED DB: PDB REMARK 900 P38ALPHA BOUND TO PYRAZOLOUREA REMARK 900 RELATED ID: 1WFC RELATED DB: PDB REMARK 900 STRUCTURE OF APO, UNPHOSPHORYLATED, P38 MITOGEN ACTIVATEDPROTEIN REMARK 900 KINASE P38 (P38 MAP KINASE) THE MAMMALIAN HOMOLOGUEOF THE YEAST REMARK 900 HOG1 PROTEIN REMARK 900 RELATED ID: 1W7H RELATED DB: PDB REMARK 900 P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1WBO RELATED DB: PDB REMARK 900 FRAGMENT BASED P38 INHIBITORS REMARK 900 RELATED ID: 1KV2 RELATED DB: PDB REMARK 900 HUMAN P38 MAP KINASE IN COMPLEX WITH BIRB 796 REMARK 900 RELATED ID: 1BMK RELATED DB: PDB REMARK 900 THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655 REMARK 900 RELATED ID: 1YQJ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH A REMARK 900 SELECTIVEPYRIDAZINE INHIBITOR REMARK 900 RELATED ID: 1BL7 RELATED DB: PDB REMARK 900 THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB220025 REMARK 900 RELATED ID: 1ZYJ RELATED DB: PDB REMARK 900 HUMAN P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1A REMARK 900 RELATED ID: 1A9U RELATED DB: PDB REMARK 900 THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB203580 REMARK 900 RELATED ID: 1WBT RELATED DB: PDB REMARK 900 IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING REMARK 900 FRAGMENT-BASED LEAD GENERATION. REMARK 900 RELATED ID: 2I0H RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38ALPHA IN COMPLEX WITH ANARYLPYRIDAZINONE REMARK 900 RELATED ID: 2BAQ RELATED DB: PDB REMARK 900 P38ALPHA BOUND TO RO3201195 REMARK 900 RELATED ID: 1WBV RELATED DB: PDB REMARK 900 IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING REMARK 900 FRAGMENT-BASED LEAD GENERATION. REMARK 900 RELATED ID: 1ZZ2 RELATED DB: PDB REMARK 900 TWO CLASSES OF P38ALPHA MAP KINASE INHIBITORS HAVING ACOMMON REMARK 900 DIPHENYLETHER CORE BUT EXHIBITING DIVERGENT BINDINGMODES REMARK 900 RELATED ID: 1DI9 RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE INCOMPLEX REMARK 900 WITH 4-[3-METHYLSULFANYLANILINO]-6,7- DIMETHOXYQUINAZOLINE REMARK 900 RELATED ID: 1W83 RELATED DB: PDB REMARK 900 P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1BL6 RELATED DB: PDB REMARK 900 THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB216995 REMARK 900 RELATED ID: 1M7Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF P38 MAP KINASE IN COMPLEX WITH REMARK 900 ADIHYDROQUINAZOLINONE INHIBITOR REMARK 900 RELATED ID: 1IAN RELATED DB: PDB REMARK 900 HUMAN P38 MAP KINASE INHIBITOR COMPLEX REMARK 900 RELATED ID: 1OZ1 RELATED DB: PDB REMARK 900 P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4- AZAINDOLEINHIBITOR REMARK 900 RELATED ID: 1WBN RELATED DB: PDB REMARK 900 FRAGMENT BASED P38 INHIBITORS REMARK 900 RELATED ID: 2BAK RELATED DB: PDB REMARK 900 P38ALPHA MAP KINASE BOUND TO MPAQ REMARK 900 RELATED ID: 1WBS RELATED DB: PDB REMARK 900 IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING REMARK 900 FRAGMENT-BASED LEAD GENERATION. REMARK 900 RELATED ID: 2BAL RELATED DB: PDB REMARK 900 P38ALPHA MAP KINASE BOUND TO PYRAZOLOAMINE REMARK 900 RELATED ID: 1OUK RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH APYRIDINYLIMIDAZOLE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1OUY RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROPYRIDO- REMARK 900 PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2Y8O RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A MAPK DOCKING REMARK 900 PEPTIDE REMARK 900 RELATED ID: 1R39 RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38ALPHA REMARK 900 RELATED ID: 1WBW RELATED DB: PDB REMARK 900 IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING REMARK 900 FRAGMENT-BASED LEAD GENERATION. REMARK 900 RELATED ID: 1KV1 RELATED DB: PDB REMARK 900 P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1 REMARK 900 RELATED ID: 1W82 RELATED DB: PDB REMARK 900 P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1OVE RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH ADIHYDROQUINOLINONE REMARK 900 RELATED ID: 1R3C RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38ALPHA C162S MUTANT REMARK 900 RELATED ID: 1W84 RELATED DB: PDB REMARK 900 P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1ZZL RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF P38 WITH TRIAZOLOPYRIDINE REMARK 900 RELATED ID: 2YIW RELATED DB: PDB REMARK 900 TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE REMARK 900 RELATED ID: 2YIX RELATED DB: PDB REMARK 900 TRIAZOLOPYRIDINE INHIBITORS OF P38 DBREF 2YIS A 2 360 UNP Q16539 MK14_HUMAN 2 360 SEQRES 1 A 359 SER GLN GLU ARG PRO THR PHE TYR ARG GLN GLU LEU ASN SEQRES 2 A 359 LYS THR ILE TRP GLU VAL PRO GLU ARG TYR GLN ASN LEU SEQRES 3 A 359 SER PRO VAL GLY SER GLY ALA TYR GLY SER VAL CYS ALA SEQRES 4 A 359 ALA PHE ASP THR LYS THR GLY LEU ARG VAL ALA VAL LYS SEQRES 5 A 359 LYS LEU SER ARG PRO PHE GLN SER ILE ILE HIS ALA LYS SEQRES 6 A 359 ARG THR TYR ARG GLU LEU ARG LEU LEU LYS HIS MET LYS SEQRES 7 A 359 HIS GLU ASN VAL ILE GLY LEU LEU ASP VAL PHE THR PRO SEQRES 8 A 359 ALA ARG SER LEU GLU GLU PHE ASN ASP VAL TYR LEU VAL SEQRES 9 A 359 THR HIS LEU MET GLY ALA ASP LEU ASN ASN ILE VAL LYS SEQRES 10 A 359 CYS GLN LYS LEU THR ASP ASP HIS VAL GLN PHE LEU ILE SEQRES 11 A 359 TYR GLN ILE LEU ARG GLY LEU LYS TYR ILE HIS SER ALA SEQRES 12 A 359 ASP ILE ILE HIS ARG ASP LEU LYS PRO SER ASN LEU ALA SEQRES 13 A 359 VAL ASN GLU ASP CYS GLU LEU LYS ILE LEU ASP PHE GLY SEQRES 14 A 359 LEU ALA ARG HIS THR ASP ASP GLU MET THR GLY TYR VAL SEQRES 15 A 359 ALA THR ARG TRP TYR ARG ALA PRO GLU ILE MET LEU ASN SEQRES 16 A 359 TRP MET HIS TYR ASN GLN THR VAL ASP ILE TRP SER VAL SEQRES 17 A 359 GLY CYS ILE MET ALA GLU LEU LEU THR GLY ARG THR LEU SEQRES 18 A 359 PHE PRO GLY THR ASP HIS ILE ASP GLN LEU LYS LEU ILE SEQRES 19 A 359 LEU ARG LEU VAL GLY THR PRO GLY ALA GLU LEU LEU LYS SEQRES 20 A 359 LYS ILE SER SER GLU SER ALA ARG ASN TYR ILE GLN SER SEQRES 21 A 359 LEU THR GLN MET PRO LYS MET ASN PHE ALA ASN VAL PHE SEQRES 22 A 359 ILE GLY ALA ASN PRO LEU ALA VAL ASP LEU LEU GLU LYS SEQRES 23 A 359 MET LEU VAL LEU ASP SER ASP LYS ARG ILE THR ALA ALA SEQRES 24 A 359 GLN ALA LEU ALA HIS ALA TYR PHE ALA GLN TYR HIS ASP SEQRES 25 A 359 PRO ASP ASP GLU PRO VAL ALA ASP PRO TYR ASP GLN SER SEQRES 26 A 359 PHE GLU SER ARG ASP LEU LEU ILE ASP GLU TRP LYS SER SEQRES 27 A 359 LEU THR TYR ASP GLU VAL ILE SER PHE VAL PRO PRO PRO SEQRES 28 A 359 LEU ASP GLN GLU GLU MET GLU SER HET YIS A1353 48 HET I46 A1354 19 HETNAM YIS 1-[3-TERT-BUTYL-1-(3-CHLORO-4-HYDROXYPHENYL)-1H- HETNAM 2 YIS PYRAZOL-5-YL]-3-{2-[(3-{2-[(2-HYDROXYETHYL) HETNAM 3 YIS SULFANYL]PHENYL}[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-6-YL) HETNAM 4 YIS SULFANYL]BENZYL}UREA HETNAM I46 2-FLUORO-4-[4-(4-FLUOROPHENYL)-1H-PYRAZOL-3-YL]PYRIDINE FORMUL 2 YIS C35 H34 CL N7 O3 S2 FORMUL 3 I46 C14 H9 F2 N3 FORMUL 4 HOH *247(H2 O) HELIX 1 1 SER A 61 MET A 78 1 18 HELIX 2 2 THR A 123 ALA A 144 1 22 HELIX 3 3 LYS A 152 SER A 154 5 3 HELIX 4 4 ALA A 184 ARG A 189 5 6 HELIX 5 5 ALA A 190 LEU A 195 1 6 HELIX 6 6 THR A 203 GLY A 219 1 17 HELIX 7 7 ASP A 227 GLY A 240 1 14 HELIX 8 8 GLY A 243 LYS A 248 1 6 HELIX 9 9 SER A 252 SER A 261 1 10 HELIX 10 10 ASN A 269 PHE A 274 1 6 HELIX 11 11 ASN A 278 LEU A 289 1 12 HELIX 12 12 ASP A 292 ARG A 296 5 5 HELIX 13 13 THR A 298 ALA A 304 1 7 HELIX 14 14 HIS A 305 ALA A 309 5 5 HELIX 15 15 GLN A 325 ARG A 330 5 6 HELIX 16 16 LEU A 333 PHE A 348 1 16 SHEET 1 AA 2 PHE A 8 LEU A 13 0 SHEET 2 AA 2 THR A 16 PRO A 21 -1 O THR A 16 N LEU A 13 SHEET 1 AB 5 TYR A 24 GLY A 31 0 SHEET 2 AB 5 SER A 37 ASP A 43 -1 O VAL A 38 N VAL A 30 SHEET 3 AB 5 ARG A 49 LYS A 54 -1 O VAL A 50 N ALA A 41 SHEET 4 AB 5 TYR A 103 HIS A 107 -1 O LEU A 104 N LYS A 53 SHEET 5 AB 5 ASP A 88 PHE A 90 -1 O ASP A 88 N VAL A 105 SHEET 1 AC 3 ALA A 111 ASP A 112 0 SHEET 2 AC 3 LEU A 156 VAL A 158 -1 O VAL A 158 N ALA A 111 SHEET 3 AC 3 LEU A 164 ILE A 166 -1 O LYS A 165 N ALA A 157 SITE 1 AC1 21 ALA A 51 LYS A 53 ARG A 67 GLU A 71 SITE 2 AC1 21 LEU A 74 LEU A 75 MET A 78 ILE A 84 SITE 3 AC1 21 LEU A 104 THR A 106 HIS A 107 MET A 109 SITE 4 AC1 21 GLY A 110 HIS A 148 SER A 154 LEU A 167 SITE 5 AC1 21 ASP A 168 PHE A 169 HOH A2032 HOH A2093 SITE 6 AC1 21 HOH A2121 SITE 1 AC2 14 PRO A 191 GLU A 192 LEU A 195 TRP A 197 SITE 2 AC2 14 PRO A 242 LEU A 246 LYS A 249 ILE A 250 SITE 3 AC2 14 ILE A 259 LEU A 291 SER A 293 HOH A2201 SITE 4 AC2 14 HOH A2233 HOH A2234 CRYST1 65.450 74.100 77.140 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.015279 0.000000 0.000000 0.00000 SCALE2 0.000000 0.013495 0.000000 0.00000 SCALE3 0.000000 0.000000 0.012963 0.00000